MOUNJARO® 7.5mg KwikPen®, 1 Stk.

MOUNJARO® 7.5mg KwikPen is a single-patient-use, multi-dose pre-filled pen containing tirzepatide — a synthetic dual GIP/GLP-1 receptor agonist developed by Eli Lilly and Company Limited — at a strength of 7.5mg per 0.6ml dose.[3][4] In the U.S., MOUNJARO® (tirzepatide) is indicated for type 2 diabetes in adults and pediatric patients aged 10 years and older; chronic weight management in the U.S. is addressed by Zepbound® (tirzepatide), a separate brand.[4] The 7.5mg dose is the intermediate titration step between 5mg and 10mg in the escalation schedule, and each KwikPen delivers four once-weekly subcutaneous doses.[3][5] Looking to buy Mounjaro 7.5mg KwikPen online? Licensed healthcare professionals are encouraged to contact Medica Depot’s support representatives for product and ordering guidance.

Product Specifications

• Drug Class: Injectable dual GIP/GLP-1 receptor agonist
• Active Substance: Tirzepatide
• Manufacturer: Eli Lilly and Company Limited
• Strength: 7.5mg per dose (0.6ml per dose — KwikPen multi-dose presentation)
• Dosage Form: Solution for injection — single-patient-use multi-dose KwikPen with 4 doses (2.4ml total; 12.5mg/ml)
• FDA Approval Date: 2022
• Regulatory Status: FDA-approved prescription pharmaceutical (type 2 diabetes); EU marketing authorization holder: Eli Lilly Nederland B.V.
• Pack Sizes: 1 pre-filled KwikPen (4 doses)
• Package Dimensions: Width: 60mm | Height: 40mm | Length: 150mm | Weight: 60g

What Is MOUNJARO® 7.5mg KwikPen?

Tirzepatide is the international non-proprietary name (INN) of the active substance in MOUNJARO®, and MOUNJARO® is the proprietary brand name Eli Lilly uses for this medicine across applicable markets and strengths.[4] The two names refer to the same molecule, but they are not interchangeable regulatory terms across all jurisdictions: in the U.S., for example, tirzepatide is marketed as MOUNJARO® for type 2 diabetes and as Zepbound® for chronic weight management — two distinct brands sharing the same active substance.[4] In the EU and certain other international markets, MOUNJARO® covers both indications under a single brand.[3]

MOUNJARO® is the first approved dual GIP and GLP-1 receptor agonist in clinical use, distinguished from conventional single-axis GLP-1 receptor agonists by its simultaneous engagement of both incretin receptor pathways.[4] The 7.5mg strength occupies the intermediate position in the titration schedule, introduced after the patient has been on the 5mg dose for a minimum of four weeks.[3][4]

In the KwikPen presentation, each multi-dose pre-filled pen contains 30mg of tirzepatide in 2.4ml of solution (12.5mg/ml), delivering four fixed doses of 7.5mg per 0.6ml subcutaneous injection for single-patient use.[3][5] This contrasts with the single-dose pre-filled pen presentation, in which the same 7.5mg strength is supplied in 0.5ml (15mg/ml) for one injection per pen. When buying online, licensed professionals should confirm which presentation — KwikPen multi-dose or single-dose pen — is appropriate for their procurement context and patient population. Professionals reviewing the full strength range can contact Medica Depot’s support representatives for ordering guidance on options to buy MOUNJARO®.

Mechanism of Action & Pharmacology

Tirzepatide is a synthetic acylated peptide that binds independently and with high affinity to both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor.[4] This dual incretin mimetic pharmacology activates each receptor pathway through distinct binding interactions, distinguishing it mechanistically from single-receptor GLP-1 agonists.[4]

At the GIP receptor, tirzepatide enhances glucose-dependent insulin secretion and supports adipose tissue lipid modulation.[4] Clinical observations suggest GIP activation may also help mitigate some of the gastrointestinal side effects typical of GLP-1 receptor agonism, though its precise contribution to tirzepatide’s overall clinical profile remains under active evaluation.[3][4]

GLP-1 receptor agonism manages glycemic control by stimulating glucose-dependent insulin secretion, suppressing inappropriate glucagon release during hyperglycemia, and delaying gastric emptying to lower postprandial blood sugar spikes.[3][4] Because both receptor pathways operate in a glucose-dependent manner, tirzepatide monotherapy carries a lower intrinsic risk of hypoglycemia than insulin secretagogues.[3][4] However, this risk increases significantly when MOUNJARO is combined with insulin or sulfonylureas.[3][4]

Data from the SURPASS phase 3 program demonstrated significant improvements in HbA1c and body weight across the dose range.[4] In the SURPASS-CVOT trial, tirzepatide met its primary endpoint of non-inferiority to dulaglutide for major adverse cardiovascular events (MACE-3), with exploratory analyses suggesting potential cardioprotective benefits.[1] Post hoc cardiorenal analyses of SURPASS-CVOT further showed a lower incidence of a broad composite cardiovascular and kidney endpoint compared to dulaglutide, providing relevant data for managing patients with concurrent cardiorenal risk profiles.[2] Prescribers should review the complete prescribing information before starting therapy.[3][4]

Indications & Patient Selection

Regional labeling determines which indications apply in a given market. In the U.S., MOUNJARO® (tirzepatide) is indicated as an adjunct to diet and exercise for glycemic control in adults and pediatric patients aged 10 years and older with insufficiently controlled type 2 diabetes mellitus — as monotherapy when metformin is not appropriate, or in addition to other antidiabetic agents.[4] MOUNJARO® does not carry a U.S. weight management indication; that indication belongs to Zepbound® (tirzepatide).[4] Clinicians outside the U.S. should consult the applicable SmPC for the current authorized indication scope.[3]

Type 2 diabetes — adults and pediatric patients (EU and U.S.)

In the EU, MOUNJARO® is indicated for adults, adolescents, and children aged 10 years and above with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise, either as monotherapy when metformin is inappropriate or in combination with other antidiabetic medicines.[3] In adult patients, the recommended maintenance doses are 5mg, 10mg, and 15mg once weekly; in the pediatric population (aged 10 years and above), the recommended maintenance doses are 5mg and 10mg, with a maximum dose of 10mg once weekly, and caution is advised when escalating to 10mg in children weighing less than 60kg.[3] The 7.5mg dose serves as a titration step for patients requiring dose escalation toward their maintenance dose after tolerating 5mg for at least four weeks.[3][4]

Chronic weight management (EU and select international markets only)

In the EU, MOUNJARO® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with a BMI ≥30 kg/m² or ≥27 kg/m² to <30 kg/m² with at least one weight-related comorbidity — including hypertension, dyslipidemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus.[3] This indication does not apply to MOUNJARO® in the U.S. Licensed professionals evaluating options to buy weight loss therapies for their patient populations can review Medica Depot’s metabolic and endocrinology catalog.

Patient selection at 7.5mg

Before prescribing the 7.5mg dose, confirm that the patient has tolerated 5mg for a minimum of four weeks.[3][4] Assess hypoglycemia risk if insulin or a sulfonylurea is co-prescribed — dose reduction of the partner agent may be required.[3][4] Evaluate renal function in patients at risk of volume depletion from gastrointestinal adverse events, and reassess management of obstructive sleep apnoea where applicable, as weight loss during treatment may alter disease severity.[3] A doctor or pharmacist should confirm jurisdiction-specific indications, applicable pack sizes, and any pediatric-specific prescribing requirements before initiating.[3][4]

MOUNJARO® is not indicated for type 1 diabetes mellitus and must not be used as a substitute for insulin.[4]

Administration & How to Use MOUNJARO® 7.5mg KwikPen

MOUNJARO 7.5mg KwikPen is administered once weekly via subcutaneous injection at any time of day, independently of meals.[3][4] Approved injection sites include the abdomen, thigh, or outer upper arm. Injection sites must be rotated weekly, avoiding areas with active bruising, scarring, infection, or lipohypertrophy.[3] If co-administered with insulin, inject MOUNJARO into a separate anatomical site.[3]

KwikPen Injection Technique

Before administration, ensure the solution is clear, colorless to slightly yellow, and free of visible particles.[3] Attach a new needle for each injection, insert subcutaneously, depress the activation button fully, and hold for 10 seconds to ensure complete delivery.[3][4] Confirm that the dose window has advanced before removing the pen, then safely discard the needle. A nurse or pharmacist should provide technique training; in pediatric populations, a caregiver should administer or supervise the injection.[3]

Pack Sizes and Storage

The standard pack contains one pre-filled KwikPen with four doses; confirm whether 3-KwikPen carton formats are available in the target market with a doctor or pharmacist at dispensing.

Missed Doses

If a dose is missed, administer it within 4 days (96 hours) of the scheduled time.[3][4] If more than 4 days have passed, skip the missed dose and resume the regular weekly schedule at the next designated day. Do not administer a double dose to compensate.[3][4]

When buying online through professional wholesale channels, licensed buyers should verify that handling requirements for temperature-sensitive pharmaceutical products are met throughout the procurement and delivery process.

Side Effects & Safety Considerations

The adverse event profile of MOUNJARO (tirzepatide) is predominantly gastrointestinal, aligning with the incretin receptor agonist class, with frequency and severity correlating to dose and titration speed.[3][4]

Most common reactions include nausea, diarrhea, vomiting, abdominal pain, constipation, dyspepsia, and decreased appetite.[3][4] These effects are typically mild-to-moderate, peak during dose escalation, and lessen over time on a stable dose.[3] If tolerability is significantly compromised, providers should consider delaying escalation or extending the current dose interval. MOUNJARO has not been evaluated in severe gastrointestinal disease, including severe gastroparesis, and requires caution in this cohort.[3]

Hypoglycemia Risk and Monitoring

While tirzepatide monotherapy carries a low intrinsic risk of low blood sugar due to its glucose-dependent mechanism, co-prescription with insulin secretagogues like sulfonylureas or insulin significantly increases this risk.[3][4] Blood glucose monitoring is advised at initiation and during titration steps, and dose reductions for the concomitant therapy should be considered.[3][4]

Serious Adverse Reactions and Contraindications

• Pancreatitis: Acute pancreatitis has occurred. Discontinue permanently if suspected; use caution in patients with a prior history.[3][4]
• Gallbladder Disease: Cholelithiasis and cholecystitis have been reported; investigate if clinical symptoms arise.[3][4]
• Renal Impairment: Dehydration from gastrointestinal events can worsen renal function. Advise patients, especially older individuals, on adequate fluid intake.[3]
• Diabetic Retinopathy: Rapid improvements in glycemic control can temporarily worsen retinopathy. Monitor patients with active proliferative retinopathy or macular edema closely.[3][4]
• Pulmonary Aspiration: Delayed gastric emptying introduces an aspiration risk during general anesthesia or deep sedation. Review fasting protocols prior to surgical procedures.[3][4]
• Obstructive Sleep Apnea: Weight reduction may modify sleep apnea severity, requiring reassessment of respiratory support parameters.[3]

Contraindications include a personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or known hypersensitivity to tirzepatide or its excipients.[3][4] Report all adverse events through local pharmacovigilance channels. Review the current SmPC or USPI for full prescribing parameters.[3][4]

Legal Status

MOUNJARO (tirzepatide) is a prescription-only pharmaceutical manufactured by Eli Lilly. In the United States, it received initial FDA approval on May 13, 2022, to improve glycemic control in type 2 diabetes as an adjunct to diet and exercise for adults, later expanding to pediatric patients aged 10 years and older.[4] U.S. chronic weight management is a distinct indication reserved for the Zepbound brand name, not MOUNJARO.[4]

In the European Union, the European Commission granted initial marketing authorization on September 15, 2022, for adult type 2 diabetes. An adult weight management indication was added in November 2023, followed by approval of the multi-dose KwikPen presentation for both indications on April 19, 2024. The type 2 diabetes indication was further extended to pediatric patients aged 10 and older following a positive CHMP opinion on December 11, 2025. The EU marketing authorization holder is Eli Lilly Nederland B.V.[3]

MOUNJARO is restricted to licensed medical professionals. Procurement, dispensing, and supply are governed by national and regional pharmaceutical regulations. Approved indications, local regulatory status, and prescribing criteria vary by jurisdiction and remain subject to revision. This data reflects publicly available regulatory information current as of the publication date.

Licensed professionals who wish to check for wholesale buying options or request current procurement guidance are encouraged to contact Medica Depot’s support representatives directly.

Disclaimer

The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.

Citations

1. Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. New England Journal of Medicine. 2025. https://www.nejm.org/doi/10.1056/NEJMoa2505928
2. Nissen SE, Wolski K, D’Alessio D, et al. Cardiorenal outcomes with tirzepatide compared with dulaglutide in patients with diabetes and cardiovascular disease: a post hoc analysis of the SURPASS-CVOT randomized clinical trial. JAMA Cardiology. 2026. https://jamanetwork.com/journals/jamacardiology/fullarticle/2847048
3. European Medicines Agency. Mounjaro — opinion on variation to marketing authorisation. 2025. https://www.ema.europa.eu/en/medicines/human/variation/mounjaro
4. Eli Lilly and Company. MOUNJARO® (tirzepatide) U.S. Prescribing Information. https://pi.lilly.com/us/mounjaro-uspi.pdf
5. Eli Lilly and Company. Mounjaro® / Mounjaro KwikPen® strengths and doses. https://www.lilly.com/en-CA/resources/faq/mounjaro-kwikpen/strengths-and-doses